摘要
目的:观察使用国产替罗非班干预对非ST段抬高ACS患者介入术后再灌注及心功能的影响。方法:选择首次因非ST段抬高ACS住院的患者79例,于入院48小时内行PCI治疗,替罗非班组38例,对照组41例。所有患者于PCI术后行心肌呈色显分级判定,在发病就诊时,PCI后第7天及6个月时行超声心动图检查,并记录住院期间及随访6个月主要临床心脏事件。结果:患者临床资料及冠状动脉造影结果无统计学差异(P>0.05);替罗非班组发生心肌无再灌注情况明显低于对照组(P<0.05);两组患者PCI术前,术后第7天,术后6个月LVEF无统计学差异,但替罗非班组PCI术后LVEF恢复好于对照组;替罗非班组住院期间及术后6个月主要心脏事件发生率较低(P>0.05)。结论:在非ST段抬高ACS行PCI治疗时应用替罗非班,可明显改善心肌再灌注,减少无复流的发生,同时改善PCI术后患者心功能,减少住院期间及术后6个月主要心脏事件发生率。
Objective: To screen the effection of tirofiban on reperfusion and heart function after percataneous coronary intervention(PCI) in patients with non-ST elevation acute coronary syndrome. Methods: The study population consisted of 79 patients with non-ST elevation acute coronary syndrome, PCI undertaken in all patients within admission 48 hours, that were designed into two groups according to tirofiban used or not: tirofiban group (38 cases) and control group (41 cases) , Myocardial blush grade (MBG)were survey. 2-dimensional echocardiography were survey at base line and seventh-day, 6-month after PCI in two groups, cardiac events were to observe. Results: The baseline clinical and angiographic was similar in two groups(P〉0.05) ;no-reperfusion in tirofiban group significantly lower than control group (P〈0.05) ;and LVEF higher in tirofihan group after PCI(P〉0.05) ; but cardiac events rate lower than control group (P〉0.05). Conclusion: In patients with non-ST elevation acute coronary syndrome, tirofiban may improve reperfusion and heart function, reduce cardiac events rate after PCI.
出处
《中国医药导刊》
2008年第1期104-106,共3页
Chinese Journal of Medicinal Guide